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Volume 52, Number 2 Abstracts 527Conclusions: Physicians with limited TEVAR experience who under-
went simulation-assisted training prior to initial TEVAR performance had
significantly fewer total number of complications than experienced physi-
cians who did not undergo simulation training, mostly due to a significant
reduction in deployment-related complications (type I endoleaks) and
stroke incidence.
A Comparison Between Single- and Two-Stage Brachiobasilic Arterio-
venous Fistulas
Tyler S. Reynolds, MD, Mohamed Zayed, MD, Karen M. Kim, MD, Jason
T. Lee, MD, Brandon Ishaque, Ramanath B. Dukkipati, MD, Amy H. Kaji,
MD, and Christian deVirgilio, MD, General Surgery, Harbor-UCLA Med-
ical Center, Torrance, CA, and Palo Alto, CA
Objectives:Controversy exists as to whether the brachiobasilic arterio-
venous fistula (BBAVF) should be performed in one or two stages. We
compare primary failure rates, as well as primary and secondary patency rates,
of one- and two-stage BBAVF.
Methods: Patients undergoing one- and two-stage BBAVF at two
institutions were compared retrospectively with respect to age, sex, body
mass index, use of preoperative venous duplex ultrasound, diabetes, hyper-
tension, and causes of end-stage renal disease. Categoric variables were
compared using 2 and Fisher exact test. The Wilcoxon rank sum test was
used to compare continuous variables. Primary and secondary patency rates
were assessed using Kaplan-Meier survival analysis and the Cox proportional
hazards model.
Results: The study identified 90 patients (60 one-stage and 30 two-
stage). Mean follow-up was 14.2 months, and the mean time interval
between the first and second stage was 11.2 weeks. Three patients in each
group required procedures to maintain assisted primary patency. Although
no significant difference in early failure existed (one-stage, 22.9% vs two-
stage, 9.1%, P  .2), the two-stage BBAVF showed significantly improved
primary patency (hazard ratio, 0.31; 95% CI, 0.09-0.99; P  .048) and
significantly improved secondary patency (hazard ratio, 0.18; 95% CI,
0.04-0.84; P  .03). Mean primary patency for one stage BBAVF was 72.3
weeks and two-stage was 138 weeks (1 SD; P  .05). Mean secondary
patency was 94 weeks and 139 weeks, respectively (1 SD; P .05). Primary
patency at 1 year for one- and two-stage stage BBAVF was 78% and 84%,
respectively (P  .05). Functional primary patency at 1 year for one- and
two-stage BBAVF was 61% and 88%, respectively (P  .05). Complication
rates were not statistically different (each greater than P  .11).
Conclusions: Patency rates appear to be improved with the two-stage
BBAVF. There is no difference in the complication rate. Optimal surgical
techniques for patients undergoing BBAVF for dialysis are discussed. Longer-
lasting hemodialysis access improves patient outcome and decreases morbid-
ity associated with dialysis.
Efficiency of the KDOQI Guidelines for Vascular Access in an Aca-
demic Setting
Traci A. Kimball, MD, Ken Barz, Kelly Dimond, MD, James Edwards, MD,
and Mark R. Nehler, MD, Department of Surgery, University of Colorado
Denver Anschutz Medical Campus, Denver, CO, Denver, CO, and Port-
land, OR
Background: The National Kidney Foundation-Kidney Disease Out-
comes Quality Initiative (KDOQI) for Vascular Access guidelines state that
late-stage chronic kidney disease (CKD) patients should undergo native
arteriovenous fistula (AVF) creation at least 6 months before the anticipated
start of hemodialysis (HD) treatments to obviate the need for other vascular
access types. The objective was to determine the incidence of HD, the
functional patency, and associated morbidity of AVFs in late-stage CKD
patients placed according to KDOQI.
Methods: Consecutive patients with late-stage CKD who underwent
“first-time” index AVF creation using K/DOQI guidelines for anatomy
between January 2003 and December 2007 at three tertiary academic
centers were retrospectively evaluated. Baseline demographics, index AVF
type, and clinical comorbidities were recorded. Patients were stratified into
one of four groups (A-D) over the follow-up course based on the patency of
their index AVF and whether or not they began HD. The ideal primary
outcome was AVF maturation and use for HD (group A; cumulative
functional patency). Other outcomes included AVF patency but no HD
(group B), HD with AVF failure (group C), or no HD and AVF abandon-
ment (group D). Secondary end points were time to first cannulation,
complications, and secondary interventions.
Results: Index AVFs were created (46% forearm and 54% upper arm) in
150 CKD patients (85% male; median age, 63 years). At a median follow-up
of 10 months, 74 patients (49%) were receiving HD and 48 (65%) were
using their index AVF (group A), while 26 (35%) were not (group C).
Thirty-four patients (23%) never initiated HD treatments, but had a viable
AVF. AVF abandonment was 51%. Mean maturation time of all index AVFs
that were cannulated was 285 days (range, 30-1265 days). Complications
encountered were maturation failure for cannulation (15%), focal stenosisrequiring intervention (13%), inadequate flows on HD (9%), steal syndrome
(9%), and thrombosis (8%). Cumulative functional patency for all index
AVFs was 19% at 6 months and 27% at 12 months, with a mean number of
two interventions per AVF (range, 1-10). Mortality for the group during the
study was 23%.
Conclusion: AVF creation in late-stage CKD patients has sobering
results. This calls into question the wisdom of early AVF planning in this
population.
Serum Metalloproteinases MMP-2, MMP-9, and Metalloproteinase
Tissue Inhibitors (TIMP) in Patients Are Associated with Arterio-
venous Fistula Maturation
Eugene S. Lee, MD, Qiang S. Shen, MD, Mingzhang Guo, PhD, Robert L.
Pitts, Mack H. Wu, MD, and Sarah Y. Yuan, MD, Surgery, UC Davis,
Sacramento, CA
Objective: Many vascular surgeons construct arteriovenous fistula
(AVF) for hemodialysis access as the primary choice access. However, a
significant number of AVF fail to mature, leading to patient frustration and
repeated operations. MMP activity, particularly MMP-2 and MMP-9, are
considered important for AVF maturation. We therefore sought to identify
whether serum MMPs could serve as a biomarker for predicting future
successful AVF maturation.
Methods:Blood was collected at the time of surgery from patients with
chronic renal insufficiency requiring long-term access. Serum was separated
from whole blood by the use of an ultracentrifuge at 1000g for 10 minutes.
Serum aliquots were frozen at –80°C until used for analysis. MMP-2,Fig.
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Patients were divided into failed and matured groups, depending on clinical
end points. Successful maturation was considered in patients who had at least
three successful hemodialysis access episodes. MMP/TIMP ratios were
calculated as an index of the MMP axis activity because MMP activity
parallels alterations in their TIMPs.
Results: Of the 20 patients who were enrolled, 13 had successful
maturation, and 7 had failure of AVFmaturation. Significantly higher serum
levels of MMP-2/TIMP-2 were found in patients who had AVF that
matured compared with those that failed (P  .003). Similarly, a trend
toward increased serum levels of MMP-9/TIMP-4 was found in patients
with successful AVF (P  .06; see Fig).
Conclusions: These data show that serum MMPs and the associated
inhibitors could potentially play a role as a biomarker for future AVF
maturation.
Blunt Abdominal Aortic Injury
Sherene Shalhub, MD, Rachel Lundgren, MD, Samantha Quade, MD, and
Benjamin Starnes,MD, Vascular Surgery, University ofWashington, Seattle,
WA
Objective: Blunt abdominal aortic injury (BAAI) is rare, with fewer
than 200 cases in the current reported world literature. It is most often seen
in high-speed motor vehicle collisions, and is associated with major blunt
intra-abdominal injury and thoracolumbar fractures. We report our institu-
tional experience over the past decade.
Methods: Of the 141 cases with blunt aortic injury presenting from
1999 to 2008, we retrospectively reviewed all cases with BAAI. Data
collected included demographics, mechanism of injury, associated injuries,
ISS, type of intervention, procedural complications, and subsequent CT
imaging.
Results:We identified BAAI in 17 patients (41% female). Average age
was 32 years (range, 6-79), and 71% were due to motor vehicle collisions. At
presentation, 40% were hypotensive. Average ISS was 49 (range, 16-75).
Associated abdominal injuries were seen in 81%, and more than half had
associated spinal injuries. Injury presentation ranged from intimal tears
(29%), intimal flaps 10 mm (29%), and pseudoaneurysms (18%), to free
rupture (24%). Treatment was nonoperative in 24%, and operative in the
majority of cases: 41% open aortic repair, 29% endovascular repair, and one
hybrid repair with visceral debranching. Overall mortality was 29%, with
most occurring in the emergency department. Free aortic rupture mortality
was 100% by hospital day 4. Procedure-related complications were one
endoleak treated with another stent graft, and visceral bypass thrombosis in
the hybrid repair case, leading to death. Follow-up imaging was available in
80%. All intimal tears treated nonoperatively healed, a large intimal flap
treated nonoperatively remained stable, and six patients who underwent
repair of their aortic injury had complete resolution and healing of their
injury.
Conclusions:This is one of the largest series described in the literature.
BAAIs range from small intimal tears to free rupture, with outcomes
correlating with injury severity. Nonoperative management was successful in
patients with intimal tears. Free rupture is associated with the highest
mortality risk. For all other categories of aortic injury, successful repair
correlates with a favorable prognosis.
Failure to Rescue: Physician Specialty and Mortality After Reoperation
for Abdominal Aortic Aneurysm (AAA) Repair
Matthew W. Mell, MD, Amy Kind, MD, Christie M. Bartels, MD, and
Maureen A. Smith,MD,MPH, PhD, Division of Vascular Surgery, Stanford
University, Stanford, CA, and University of Wisconsin, Madison, WI
Objectives: Complications after AAA repair resulting in reoperation
contribute to mortality, but have not been well studied. Mortality after
reoperation is termed failure to rescue, and may reflect differences in
outcome directly related to management of the complication. This study
describes the relationship between reoperation and mortality and demon-
strates the effect of physician specialty on reoperation rates and failure to
rescue after AAA repair.
Methods:Data were extracted for 2616 patients who underwent intact
AAA repair in 2005-2006 from a standard 5% random sample of all Medicare
beneficiaries. Patient demographics, comorbidities, type of repair, and spe-
cialty of operating surgeon were collected. Primary outcomes were 30-day
reoperation and 30-day mortality. Logistic regression analysis identified
characteristics predicting reoperation.
Results: A total of 156 reoperations were required in 142 patients
(4.2%). Early mortality was far more likely after reoperation (22.5% vs 1.5%;
P .0001). Of patients requiring reoperation, those requiring two or more
interventions had an even highermortality (54% vs 20%; P .0007). Despite
equivalent need for reoperation among specialties (vascular surgeons, 5.2%;
others, 5.6%, P  .67), the mortality after reoperation was nearly half for
vascular surgeons compared with other specialties (16.2% vs 32.3%; P 
.04). The most common reason for reoperation was arterial complications(35.8%; mortality, 39.3%), which also accounted for the largest difference in
mortality between vascular surgeons (30.7%) and other specialties (52.0%).
Conclusions: Postoperative complications requiring reoperation dra-
matically increase mortality after AAA repair. Lower mortality after reopera-
tion in patients managed by vascular surgeons reflects the importance of
specialty vascular care. Failure to rescue contributes to the difference in
outcome given equivalent complication rates.
Clinical Outcomes and Volumetric Analysis of Endoluminal Exclusion
of Acute Complicated Type B Descending Thoracic Aortic Dissections
Karen M. Kim, MD, Carlos E. Donayre, MD, Tyler S. Reynolds, MD,
George E. Kopchok, Irwin Walot, MD, Joe P. Chauvapun, MD, and
Rodney A. White, MD, Harbor UCLA Medical Center, Torrance, CA
Objective: Late clinical outcomes and structural changes within the
aorta after thoracic endovascular aortic repair (TEVAR) for acute compli-
cated type B descending thoracic aortic dissections (ADTD) remain un-
known. The goal of the study is to review and analyze the clinical outcomes
and the volumetric data of patients with ADTD.
Methods: From 2002 to 2009, 41 consecutive patients with ADTD,
all with at least 1 year of follow-up, were treated as a part of a single center
FDA-approved IDE. Indications were malperfusion (n 17), rupture (n
12), chest pain (n  6), acute enlargement (n  4), and uncontrolled
hypertension (n  2). Duration of symptoms was 14 days. We analyzed
3-D M2S CT reconstructions for aortic volume and diameter changes,
regression of the false lumen, and expansion of the true lumen.
Results: Thirty-two patients (78%) required emergent surgery, with
one death at induction. Procedural success rate was 97%. The 30-day
mortality was 14% for malperfusion, 25% for rupture, and 0% for all others,
with late mortality of 0%, 25%, and 25%, respectively. Mean follow-up was
18 months. Permanent stroke and paraplegia rates were 4.9% (n  2) and
0%. Ten of 18 secondary interventions were performed for 5 proximal
endoleaks, 1 distal cuff endoleak, and 4 distal reperfusions. For 33 patients
without endoleaks, the true lumen volume grew by 29% at 1 month, 51% at
1 year, and 80% at 5 years. Volume regression of the false lumen was 69%,
76%, and 86%, respectively. The true lumen volume did not change at 1
month or 1 year in the endoleak group (n 7) but increased 50% at 2 years
after secondary intervention. A 10% reduction of abdominal aortic volume
distal to endograft occurred over 5 years in the absence of endoleaks.
Conclusions: TEVAR offers a promising solution to patients with
ADTD. Aortic morphologic changes occur shortly after TEVAR and remain
predictable up to 5 years with continuous expansion of the true lumen and
regression of the false lumen. A lack of increase in the true lumen volume is
associated with endoleaks or distal reperfusion.
Gender-based Outcomes Following Endovascular Repair of Degener-
ative Thoracic Aneurysms
Karthikeshwar Kasirajan, MD, Emory University School of Medicine, At-
lanta, GA
Sponsored by: Peter Schneider, MD
Objective: The extent to which patient gender influences endograft
treatment of TA has not been reported. The current study analyzed the
influence of gender on the endovascular management of thoracic aneurysms.
Methods: A total of 421 patients (265 males [M] and 156 females [F])
were enrolled as part of the TAG (WL Gore, Flagstaff, AZ) thoracic stent
graft trials. Preoperative risk factors, intraoperative events, and 365-day
follow-up data were analyzed.
Results: The mean maximal aneurysm diameter was comparable (M,
63; vs F, 60 mm; P  .09). Among 22 different preoperative risk factors
evaluated, women had a lower incidence of prior vascular procedures (P 
.004), and a trend was noted towards lower coronary artery disease and
smoking (P  .09, P  .08). Mean proximal and distal landing zone
diameters and iliac access diameters (M, 9.2; vs F, 7.6 cm) were smaller in
women (P .001). Conduits were required more frequently among women
(M, 6%; vs F, 24%; P  .001). Local access site complications were signifi-
cantly higher in women, most related to vascular trauma (M, 2%; vs F, 12%).
Overall length of stay was prolonged in women (M, 4.8; vs F, 5.5 days; P
.001). However, this did not result in any difference between genders in the
technical success rate (device delivery and successful aneurysm exclusion) or
any other major adverse event rate (P .82) at 30 and 365 days. Survival at
1 year was comparable (M, 91%; vs F, 87%; P  .229).
Conclusion:No significant difference in major end points was noted at
1 month and 1 year on gender-based analysis for thoracic stent graft therapy.
Local access complications may have been related to the smaller access
vessels diameter for female patients. A great attention to detail for the access
site in women and a lower threshold for elective conduit may be a more
prudent approach.
